Yeray Brito-Casillas
Overview
Explore the profile of Yeray Brito-Casillas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hafez L, Brito-Casillas Y, Abdelmageed N, Aleman-Cabrera I, Morad S, Abdel-Raheem M, et al.
Nutrients
. 2025 Jan;
16(24.
PMID: 39770900
For thousands of years, has been widely used as an herbal medicine to treat some diseases and symptoms, including respiratory, gastrointestinal and urogenital ailments. The present study was adapted to...
2.
Lilao-Garzon J, Brito-Casillas Y, Quesada-Canales O, Wagner A, Munoz-Descalzo S
Reproduction
. 2023 Oct;
166(3):235-245.
PMID: 37889771
In Brief: Fertility has decreased due to advanced maternal age and the rising prevalence of the metabolic syndrome. Using quantitative image analysis methods, we show that these factors are associated...
3.
Suarez N, Jebari-Benslaiman S, Jimenez-Monzon R, Benito-Vicente A, Brito-Casillas Y, Garces L, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511081
The p.(Tyr400_Phe402del) mutation in the LDL receptor () gene is the most frequent cause of familial hypercholesterolaemia (FH) in Gran Canaria. The aim of this study was to determine the...
4.
Perez-Lopez L, Boronat M, Melian C, Santana A, Brito-Casillas Y, Wagner A
Vet Med Sci
. 2023 Jan;
9(2):572-578.
PMID: 36639961
Background: Obesity has been proposed as an independently risk factor for chronic kidney disease (CKD) in people, but its role in feline kidney function is unknown. Objective: Obesity has been...
5.
Cabrera-Galvan J, Araujo E, de Mirecki-Garrido M, Perez-Rodriguez D, Guerra B, Aranda-Tavio H, et al.
Biomed Pharmacother
. 2022 Dec;
157:114060.
PMID: 36455458
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers worldwide, but the precise intracellular mechanisms underlying the progression of this inflammation associated cancer are not well established....
6.
Guerra-Rodriguez M, Lopez-Rojas P, Amesty A, Aranda-Tavio H, Brito-Casillas Y, Estevez-Braun A, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358593
Tamoxifen improves the overall survival rate in hormone receptor-positive breast cancer patients. However, despite the fact that it exerts antagonistic effects on the ERα, it can act as a partial...
7.
Brito-Casillas Y, Caballero M, Hernandez-Baraza L, Sanchez-Hernandez R, Betancort-Acosta J, Wagner A
Gastroenterol Hepatol
. 2022 Oct;
46(6):455-461.
PMID: 36273654
Aim: To investigate the mucoadhesive strength and barrier effect of Esophacare® (Atika Pharma SL, Las Palmas de Gran Canaria) in an ex vivo model of gastro-oesophageal reflux. Methods: An ex...
8.
Sanz F, Solana-Manrique C, Lilao-Garzon J, Brito-Casillas Y, Munoz-Descalzo S, Paricio N
FASEB J
. 2022 Jun;
36(8):e22432.
PMID: 35766235
Parkinson's disease (PD) is the second most common neurodegenerative disease. Diabetes mellitus (DM) is a metabolic disease characterized by high levels of glucose in blood. Recent epidemiological studies have highlighted...
9.
Lopez-Rojas P, Amesty A, Guerra-Rodriguez M, Brito-Casillas Y, Guerra B, Fernandez-Perez L, et al.
Pharmaceuticals (Basel)
. 2022 May;
15(5).
PMID: 35631411
Based on molecular docking studies on the ERα, a series of lignan derivatives (-) were designed and semisynthesized from the natural dibenzylbutyrolactones bursehernin () and matairesinol dimethyl ether (). To...
10.
Aranda-Tavio H, Recio C, Martin-Acosta P, Guerra-Rodriguez M, Brito-Casillas Y, Blanco R, et al.
Biomed Pharmacother
. 2021 Oct;
144:112330.
PMID: 34673425
Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently...